Shannon John Patrick Jr's Form 4 filing

Xeris Biopharma Holdings, Inc. (XERS) · filed Nov 12, 2021

Accession no.: 0001867096-21-000077
Filed: Nov 12, 2021
Trade date: Nov 11-12, 2021
Filing delay: 1 day
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market purchases total $209.6K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Shannon John Patrick JrCIK 0001553595	Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Nov 11, 2021	Common Stock	PPurchaseAcquired	+40,000	$2.09^F1	+$83,600	303,829	Direct
Nov 12, 2021	Common Stock	PPurchaseAcquired	+60,000	$2.10^F2	+$126,000	363,829	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.08 to $2.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.09 to $2.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Remarks

President and Chief Operating Officer

Read the full filing on SEC EDGAR (opens in a new tab)